Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for Lucid-21-302 (Lucid-MS), targeting submission to the FDA in Q4 2025. The successful IND application will enable the company to proceed with Phase 2 trials for multiple sclerosis treatment.
Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action. This patented New Chemical Entity has demonstrated ability in preclinical models to prevent demyelination, a known cause of MS and other neurodegenerative diseases affecting the myelin sheath around nerve fibers.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment by purchasing an additional USD $1 million worth of Bitcoin and other cryptocurrencies, bringing its total digital asset investment to USD $4.5 million. The purchase, approved by the Board of Directors, is part of the company's strategic initiative to hedge against the Canadian dollar and generate returns for shareholders. The company has established infrastructure to accept cryptocurrency-based financing and execute other transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions, while ensuring compliance with financial and audit regulations.
Quantum BioPharma (NASDAQ: QNTM) has announced its participation in two upcoming investor conferences in May 2025. The company's Head of Finance and M&A, Jason Sawyer, will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22.
At the Sidoti conference, Mr. Sawyer will deliver a webcast presentation from 9:15-9:45 AM ET and conduct one-on-one meetings with institutional investors. The following day at the A.G.P. conference, he will participate in virtual one-on-one meetings with investors. Interested parties can schedule meetings through conference representatives or by contacting QNTM@mzgroup.us.
Quantum BioPharma (NASDAQ: QNTM) has completed the dosing phase of 90-day oral toxicity and toxicokinetic studies for its Multiple Sclerosis drug candidate Lucid-21-302 (Lucid-MS). These studies are crucial for supporting an upcoming Investigational New Drug (IND) application with the US FDA, which the company aims to submit by the end of 2025. The completion of these toxicity studies marks a significant step toward initiating a Phase 2 trial for Lucid-MS, which is being developed as a first-in-class treatment for Multiple Sclerosis patients.
Quantum BioPharma (NASDAQ: QNTM) has filed an amended complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD. The lawsuit alleges that between January 2020 and August 2024, the defendants engaged in market manipulation through "spoofing" techniques, violating multiple sections of the Securities Exchange Act of 1934.
The company's stock, which traded above $460 USD per share in January 2020 with a market cap approaching $1 billion, was allegedly artificially depressed by hundreds of spoofing incidents. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis, eliminating material financial pressure on Quantum BioPharma for legal costs.
Quantum BioPharma (NASDAQ: QNTM) has announced a Business Update Conference Call scheduled for Tuesday, May 6, 2025, at 4:30 p.m. Eastern time. The call will feature CEO Zeeshan Saeed and Head of Finance Jason Sawyer discussing:
- Year-end financial results
- Regulatory initiatives
- Commercial-readiness activities
- Anticipated milestones
The presentation will be available during the webcast and afterward through the company's investor relations section. Participants can join via:
- US Dial-in: 1-877-407-9716
- International: 1-201-493-6779
- Conference Code: 13753539
A replay will be available until August 6, 2025, accessible through US (1-844-512-2921) and international (1-412-317-6671) numbers with pin 13753539.
Quantum BioPharma (NASDAQ: QNTM) has appointed Kevin Malone as an advisor to the Board of Directors. Malone, a second-generation financial advisor with over 40 years of family experience in wealth management, founded Malone Wealth in 2021. He specializes in pattern recognition and data research, focusing on fighting market corruption and naked short selling.
Malone's expertise includes identifying undervalued assets and tactical investment rebalancing. He has established a charitable fund aimed at incorporating financial literacy into the US Public Education System. Zeeshan Saeed, CEO of Quantum BioPharma, welcomed Malone's appointment, particularly highlighting his experience in naked short squeeze strategies and combating stock manipulation.
Quantum BioPharma (NASDAQ: QNTM) has secured a significant legal victory as the Court of Appeal for Ontario dismissed a reconsideration motion filed by Dr. Raza Bokhari, former CEO of FSD Pharma (now Quantum BioPharma). The court's decision upholds awards totaling $180,000 in Quantum's favor.
The dispute stems from Dr. Bokhari's termination for cause in July 2021. Previously, Arbitrator Cunningham rejected Dr. Bokhari's wrongful dismissal claim and awarded the company approximately CDN$2.81 million in arbitration costs plus interest. The U.S. District Court for Eastern Pennsylvania granted judgment in Quantum's favor, including various monetary awards with interest rates ranging from 4% to 6% per annum.
Dr. Bokhari has appealed the U.S. Court order and received a stay after providing a supersedeas bond for USD $2,882,441.48. The final judgment from the United States Court of Appeals for the Third Circuit is pending.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition has formed a strategic partnership with the Asian American Trade Associations Council (AATAC) to expand the retail distribution of unbuzzd™, their alcohol detox beverage.
The partnership focuses on unbuzzd™'s On-the-Go Powder Stick Packs, which are scientifically proven to accelerate blood alcohol level reduction and restore mental alertness. AATAC represents over 50,000 members operating more than 80,000 locations, including major convenience store chains like 7-Eleven, Shell, Circle K, and BP.
This collaboration aims to increase sales and product accessibility across the United States and Puerto Rico, leveraging AATAC's extensive network of convenience stores and their experience in launching successful consumer goods products.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition is launching unbuzzd™, an alcohol detoxification and anti-hangover beverage, in Puerto Rico through FUSION Distribution Group.
unbuzzd™, scientifically validated through a double-blind placebo-controlled crossover study, is designed to accelerate alcohol metabolism and reduce hangover symptoms. The product will be available in single-serve powder stick packs through FUSION's extensive retail network, including major retailers like Walmart, Walgreens, Costco, Sam's, and various supermarket chains.
FUSION Distribution Group, which already distributes notable brands like CELSIUS Energy Drinks and Kin Whiskey, will initially launch unbuzzd™ in Puerto Rico before expanding across the Caribbean region. The product will be available in grocery stores, pharmacies, convenience stores, hotels, bars, and restaurants.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
